Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 621
Aptamer sequence: GGAATGGATCCACATCCATGGATGGGCAATGCGGGGTGGAGAATGGTTGCCGCACTTCGGCTTCACTGCAGACTTGACGAAGCTT
Target unique ID: 5754
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_587 Aptamer 15-1 Molecule Hydrocortisone 6.9 μM 50 mM Tris, 137 mM NaCl, 5 mM MgCl2, pH 7.4 24880870
Structure information of aptamer
Aptamer Sequence: GGAATGGATCCACATCCATGGATGGGCAATGCGGGGTGGAGAATGGTTGCCGCACTTCGGCTTCACTGCAGACTTGACGAAGCTT
The optimal secondary structure in dot-bracket notation: ...((((((....))))))(((((((((((...............)))))).)).)))((((((..............)))))).
The centroid secondary structure in dot-bracket notation: ...(((((......))))).......................................((((((..............)))))).
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_587 Description Aptamer 15-1
Aptamer chemistry DNA Length 85 nt
GC content 55.3% Molecular weight 26,380.86 Da
Molarity of 1 μg/μl solution 37.91 μM Number of G-quadruplexes 2
G-Score 19 Function Aptasensor
Sequence GGAATGGATCCACATCCATGGATGGGCAATGCGGGGTGGAGAATGGTTGCCGCACTTCGGCTTCACTGCAGACTTGACGAAGCTT
Applications Detection of cortisol
Target information
Type Detail Type Detail
PubChem ID 5754 Molecular name Hydrocortisone
Molecular formula C21H30O5 Molecular weight 362.5
IUPAC name (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one InChIKey JYGXADMDTFJGBT-VWUMJDOOSA-N
LogP 1.782 Topological polar surface area 94.83
Hydrogen bond acceptor 5 Hydrogen bond donor 3

Synonym(s):
hydrocortisone; Cortisol; 50-23-7; Acticort; Cetacort; Hydrasson; Hydrocortisyl; Cobadex; Cortef; Hydrocortone; Hycort; Hytone; Signef; 17-Hydroxycorticosterone; Optef; Kendall's compound F; Cortanal; Cortenema; Corticreme; Cortifan; Cortiment; Cortispray; Cortonema; Dermacort; Dermolate; Efcorbin; Efcortelan; Ficortril; Genacort; Hycortol; Hycortole; Permicort; Proctocort; Tarcortin; Traumaide; Alacort; Cleiton; Cortril; Dihydrocostisone; Hytone lotion; Hidro-Colisona; Hydro-Adreson; Scheroson F; Incortin-H; Reichstein's substance M; Cort-Dome; Domolene-HC; Epiderm H; Esiderm H; Otosone-F; Polcort H; Cortolotion; Cortoxide; Cremesone; Eldercort; Heb-Cort; Maintasone; Delacort; Dioderm; Eldecort; Epicort; Mildison; Penecort; Rectoid; Anflam; Hydrocorticosterone; Hydroxycortisone; H-Cort; Hydro-Colisona; Cortisol alcohol; Incortin-hydrogen; Ala-Scalp; Aeroseb-HC; Barseb HC; Dermocortal; Nutracort; Synacort; Timocort; Evacort; Komed HC; Hydrocortisone base; Lacticare-HC; Texacort lotion 25; Ala-Cort; Anti-inflammatory hormone; Hydrocortisone alcohol; Algicirtis; Aquacort; Cortesal; Cortisolonum; Flexicort; Hidalone; Hytisone; Kyypakkaus; Lactisona; Lubricort; Meusicort; Milliderm; Sanatison; Schericur; Sigmacort; Stiefcorcil; Texacort; Amberin; Cutisol; Dermil; Uniderm; Foille Insetti; Gyno-Cortisone; Transderma H; Basan-Corti; Clear aid; Cremicort-H; Dome-cort; Neosporin-H Ear; Remederm HC; Aquanil HC; Cortisporin Otico; Derm-Aid; Heb Cort; Scalpicin Capilar; Systral Hydrocort; Prevex HC; Cortisporin; Efcortelin; Fiocortril; Hidrocortisona; Hydrocortisone free alcohol; Hydrocortisonum; Proctofoam; Alphaderm; Hydracort; Medicort; Otocort; Zenoxone; Drotic; Vytone; 11beta-Hydroxycortisone; Nystaform-HC; Aeroseb HC; CaldeCORT Spray; Pediotic Suspension; VoSol HC; Idrocortisone; 17alpha-Hydroxycorticosterone; Hydrocortal; Hydroskin; Otalgine; Otobiotic; Protocort; Hysone; Racet; Ef corlin; 11beta-Hydrocortisone; Compound F; Lacticare HC; Compound F (kendall); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; Hydrocortisone (Cortisol); Chronocort; Hydrocort; Plenadren; Preparation H Hydrocortisone Cream; Neo-Cort-Dome; 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione; Otic-Neo-Cort-Dome; 11beta,17,21-Trihydroxypregn-4-ene-3,20-dione; NSC 10483; HC; UNII-WI4X0X7BPJ; [3H]cortisol; (11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione; Prestwick_265; 4-Pregnene-11beta,17alpha,21-triol-3,20-dione; CHEBI:17650; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione; NSC10483; 11.beta.-Hydrocortisone; Dermaspray; MFCD00011654; NSC-10483; WI4X0X7BPJ; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 11beta,17,21-Trihydroxyprogesterone; 11.beta.-Hydroxycortisone; Ophthocort; Terra-cortril; MLS000069609; 17.alpha.-Hydroxycorticosterone; Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; 4-Pregnen-11beta,17alpha,21-triol-3,20-dione; Idrocortisone [DCIT]; Genacort (lotion); Anucort; Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; Prepcort; SMR000059022; DSSTox_CID_714; Hydrocortisonum [INN-Latin]; Proctozone HC; Scalp-Cort; Hidrocortisona [INN-Spanish]; Rectasol-HC; Anucort-HC; Hydro-RX; DSSTox_RID_75753; DSSTox_GSID_20714; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; HC (HYDROCORTISONE); Corhydron; (11alpha,14beta)-11,17,21-Trihydroxypregn-4-Ene-3,20-Dione; DuoCort; HYDROCORTISONE IN ABSORBASE; Proctosol-HC; HC #1; HC #4; Acticort (TN); Colocort (TN); (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one; SMR000653523; Cortef (TN); Hytone (TN); Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CCRIS 5854; component of Otalgine; Anusol HC (TN); component of Lubricort; COR-OTICIN; HSDB 3339; EINECS 200-020-1; component of Neo-Cort-Dome; Cortizol; Efmody; AI3-25006; 3h-cortisol; 11beta-cortisol; CAS-50-23-7; 11-Hydrocortisone; Plenadren (TN); NCGC00022848-06; 11b-Hydrocortisone; Kendalls compound F; Hydrocortisone [USP:INN:BAN:JAN]; Drotic (Salt/Mix); 11b-Hydroxycortisone; Otocort (Salt/Mix); Pregn-4-ene-3,20-dione, 11beta,17,21-trihydroxy-; Otalgine (Salt/Mix); Hydrocortisone, 98%; 11,17,21-Trihydroxypregn-4-ene-3,20-dione; Alphaderm (Salt/Mix); Hydrocortisone, topical; Otobiotic (Salt/Mix); Reichsteins substance M; 4p6x; Cort-Quin (Salt/Mix); Cortisporin (Salt/Mix); VoSol HC (Salt/Mix); 11a-Hydroxycorticosterone; 17a-Hydroxycorticosterone; Opera_ID_1292; Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11-beta)-; Prestwick0_000447; Prestwick1_000447; Prestwick2_000447; Prestwick3_000447; Epitope ID:174851; UPCMLD-DP133; EC 200-020-1; H 4001; SCHEMBL4148; Neo-Cort-Dome (Salt/Mix); Lopac0_000594; 11alpha-Hydroxycorticosterone; BSPBio_000494; MLS001148103; MLS002207135; MLS002222189; MLS002548868; SPBio_002433; BPBio1_000544; CHEMBL389621; GTPL2868; Pediotic Suspension (Salt/Mix); DTXSID7020714; UPCMLD-DP133:001; BDBM13775; Otic-Neo-Cort-Dome (Salt/Mix); 2v95; Hydrocortisone (JP17/USP/INN); HMS1569I16; HMS2090M04; HMS2096I16; HMS2230B18; HMS2235F17; HMS3259C05; HMS3261H10; HMS3713I16; Hydrocortisone, >=98% (HPLC); Vioform-Hydrocortisone (Salt/Mix); 11b,17,21-Trihydroxyprogesterone; BCP09054; HY-N0583; Tox21_110883; Tox21_200815; Tox21_500594; LMST02030001; s1696; ZINC13540519; AKOS001582651; Tox21_110883_1; CCG-204683; DB00741; LP00594; MCULE-8953627920; NC00456; SDCCGSBI-0050576.P003; 11.beta.,17,21-trihydroxyprogesterone; SMP1_000156; NCGC00022848-07; NCGC00022848-09; NCGC00022848-10; NCGC00022848-11; NCGC00022848-12; NCGC00022848-13; NCGC00022848-14; NCGC00022848-15; NCGC00022848-17; NCGC00022848-26; NCGC00258369-01; NCGC00261279-01; (1S,10S,11S,15S,17S,2R,14R)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyl tetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; AC-12902; AS-11651; BP-20390; NCI60_000118; 4-Pregnene-11alpha,21-triol 3,20-dione; B1951; EU-0100594; 4-Pregnene-11b,17a,21-triol-3,20-dione; 50H237; 6861-EP2269977A2; 6861-EP2270008A1; 6861-EP2277565A2; 6861-EP2277566A2; 6861-EP2277567A1; 6861-EP2277568A2; 6861-EP2277569A2; 6861-EP2277570A2; 6861-EP2292227A2; 6861-EP2292280A1; 6861-EP2292615A1; 6861-EP2292617A1; 6861-EP2295409A1; 6861-EP2298778A1; 6861-EP2305679A1; 6861-EP2308562A2; 6861-EP2314590A1; 6861-EP2371811A2; 7062-EP2269977A2; 7062-EP2292228A1; 7062-EP2295411A1; 7062-EP2298747A1; 7062-EP2301931A1; 7062-EP2308851A1; 7062-EP2308880A1; 7062-EP2311811A1; 7062-EP2314585A1; C00735; D00088; J10114; U 1851; 92372-EP2280008A2; 92372-EP2289483A1; 92372-EP2305257A1; Hydrocortisone, meets USP testing specifications; Pregn-4-ene-3, 11.beta.,17,21-trihydroxy-; 11?,17?,21-Trihydroxypregn-4-ene-3,20-dione; A929789; Hydrocortisone, VETRANAL(TM), analytical standard; Q190875; SR-01000000139; Q-201211; SR-01000000139-3; 11.beta.,17,21-Trihydroxypregn-4-ene-3,20-dione; BRD-K93568044-001-03-1; BRD-K93568044-001-11-4; BRD-K93568044-001-32-0; Hydrocortisone, BioReagent, suitable for cell culture; 4-Pregnen-11.beta.,17.alpha.,21-triol-3,20-dione; 4-Pregnene-11.beta.,17.alpha.,21-triol-3,20-dione; Pregn-4-ene-3,20-dione, 11.beta.,17,21-trihydroxy-; Z2786051549; (11beta)-11,17,21-Trihydroxy-pregn-4-ene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxy-4-pregnene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxypregn-4-ene-3,20-dione; B48448A1-24BA-47CA-8D9E-43E5BC949386; Hydrocortisone, British Pharmacopoeia (BP) Assay Standard; Pregn-4-ene-3, 11,17,21-trihydroxy-, (11.beta.)-; 11,17,21-Trihydroxypregn-4-ene-3,20-dione, (11.beta.)-; Hydrocortisone, European Pharmacopoeia (EP) Reference Standard; Hydrocortisone, United States Pharmacopeia (USP) Reference Standard; Hydrocortisone-Water Soluble, BioReagent, suitable for cell culture; Hydrocortisone, gamma-irradiated, powder, BioXtra, suitable for cell culture; 4-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(3-methoxyphenyl)piperidine-1-carboxamide; Cortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Hydrocortisone for peak identification, European Pharmacopoeia (EP) Reference Standard; Hydrocortisone solution, 50 muM, sterile-filtered, BioXtra, suitable for cell culture; Hydrocortisone, Pharmaceutical Secondary Standard; Certified Reference Material; (10R,13S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one']

Activity data
Interaction ID 621
Target type Molecule
Target unique ID 5754
Activity 6.9 μM
Binding Conditions/Buffer

50 mM Tris, 137 mM NaCl, 5 mM MgCl2, pH 7.4

Assay

MST Kd measurement of aptamer 15-1 and cortisol

PubMed ID 24880870
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_495 DNA GGGAATGGATCCACATCTACGTATTACTGCTGGTGACGAGGGCTAGACGACGTACCTTCACTGCAGACTTGACGAAGCTT 72.94%
Apta_1118 DNA GGGAATGGATCCACATCTACGAATTCATCAGGGCTAAAGAGTGCAGAGTTACTTAGTTCACTGCAGACTTGACGAAGCTT 71.76%
Apta_1119 DNA GGGAATGGATCCACATCTACGAATTCGGTTGTGAAGATTGGGAGCGTCGTGGCTACTTCACTGCAGACTTGACGAAGCTT 71.76%
Apta_1120 DNA GGGAATGGATCCACATCTACGAATTCGGAATGAGTGCCCTGCAAGCGAGGGCTAGCTTCACTGCAGACTTGACGAAGCTT 69.41%
Apta_623 RNA GGGAAUGGAUCCACAUCUACGAAUUCACCGCGGGGUUGCGGACCGGGAGCUCCAGCUUCACUGCAGACUUGACGAAGCUU 60.00%
Apta_589 DNA GGGAATTCGAGCTCGGTACCATCTGTGTAAGGGGTAAGGGGTGGGGGTGGGTACGTCTAGCTGCAGGCATGCAAGCTTGG 54.12%
Apta_810 DNA ACAGCATCCCCATGTGAACAATCGCATTGTGATTGTTACGGTTTCCGCCTCATGGACGTGCTG 54.12%
Apta_887 DNA ACGCTCGGATGCCACTACAGGGGGGTGGTCCTGAGGGTGGTGTGGTTGGTTTGGTTTCCTCATGGACGTGCTGGTGAC 54.12%
Apta_589 DNA GGGAATTCGAGCTCGGTACCATCTGTGTAAGGGGTAAGGGGTGGGGGTGGGTACGTCTAGCTGCAGGCATGCAAGCTTGG 54.12%
Apta_1101 DNA CCGTAATACGACTCACTATAGGTATGTGACGCGCGTCAATCGCTGTCCTACCAAGCTTTGCAGAGAGGATCCTT 52.94%
Apta_409 DNA GCAATGGTACGGTACTTCCGGATGCGGAAACTGGCTAATTGGTGAGGCTGGGGCGGTCGTGCAGCAAAAGTGCACGCTACTTTGCTAA 52.27%
Apta_951 DNA CACCTAATACGACTCACTATAGCGGATCCGAGGGGGTAGCGGGTGGGCCGGTGGATGCGGGGCGCCGGCGCCTGGCTCGAACAAGCTTGC 52.22%
Apta_625 DNA ATACCAGCTTATTCAATTCAGGGCGGTATGAGGCTCGATCAAGGTCGGAGCGAGAATTTTTTCGCGGAGTCGGCTGGATCAGATAGTAAGTGCAATCT 52.04%
Apta_625 DNA ATACCAGCTTATTCAATTCAGGGCGGTATGAGGCTCGATCAAGGTCGGAGCGAGAATTTTTTCGCGGAGTCGGCTGGATCAGATAGTAAGTGCAATCT 52.04%
Apta_67 DNA AGATGCCTGTCGAGCATGCTGTTGTGGTAGGGTTAGGGATGGTAGCGGTTGTAGCTAAACTGCTTTGTCGACGGG 51.76%
Apta_68 DNA AGATGCCTGTCGAGCATGCTGTGAATAGGTAGGGTCGGATGGGCTACGGTGTAGCTAAACTGCTTTGTCGACGGG 51.76%
Apta_140 DNA GGCAGGAAGACAAACACGATGGGGGGGTATGATTTGATGTGGTTGTTGCATGATCGTGGTCTGTGGTGCTGT 51.76%
Apta_408 DNA GCAATGGTACGGTACTTCCGTCATCAGCTTGTGATGTGGATGCGAACTGCAAAAGTGCACGCTACTTTGCTAA 51.76%
Apta_417 DNA GGCAGGAAGACAAACACCAGGTGAGGGAGACGACGCGAGTGTTAGATGGTAGCTGTTGGTCTGTGGTGCTGT 51.76%
Apta_464 DNA GTCAGATTCCACTATAGTAGGTTGGGTAGGGTGGTCGCAGTGGATGATATGTCGTAGGGG 51.76%